PET scans reveal how ketamine rewires glutamate receptors to lift treatment-resistant depression

About 30% of people with major depressive disorder do not respond to conventional antidepressants. For these patients, ketamine has emerged as a rapid-acting alternative, often producing noticeable improvement within hours rather than weeks. But a fundamental question has lingered: what is ketamine actually doing in the human brain to produce this effect?

A study published March 5, 2026, in Molecular Psychiatry provides the most direct answer yet. A team led by Professor Takuya Takahashi at Yokohama City University used a specialized PET imaging tracer to watch ketamine reshape the distribution of a key brain receptor in real time, revealing that the drug's benefit comes not from a uniform chemical wash across the brain, but from precise, region-by-region adjustments.

Seeing AMPA receptors in living brains

The receptor in question is the AMPA receptor (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor), a protein that sits at synapses and plays a central role in how neurons communicate. Animal studies have long implicated AMPA receptors in ketamine's antidepressant mechanism, but confirming this in humans required a tool that did not exist until recently.

Takahashi's team previously developed a PET tracer called [11C]K-2 that binds specifically to AMPA receptors on the surface of neurons in the living brain. This tracer allowed them to measure receptor density before and after treatment, region by region, in human patients for the first time.

34 patients, three clinical trials

The study integrated data from three registered clinical trials conducted in Japan. Thirty-four patients with treatment-resistant depression and 49 healthy controls underwent PET imaging. Patients received either intravenous ketamine or placebo over a two-week period, with brain scans performed before the first infusion and after the last.

Before treatment, patients with treatment-resistant depression showed widespread abnormalities in AMPA receptor density compared to healthy participants. The receptors were distributed differently across brain regions, suggesting that the receptor landscape itself is altered in depression that resists conventional treatment.

Not a uniform effect

Ketamine did not simply increase or decrease AMPA receptors everywhere. Instead, clinical improvement was associated with dynamic, region-specific changes. Receptor density increased in several cortical regions, areas involved in cognitive processing and emotional regulation. At the same time, receptor density decreased in reward-related areas, particularly the habenula, a small structure that has been implicated in processing negative outcomes and that appears overactive in depression.

These bidirectional changes correlated with reductions in depressive symptoms. Patients who showed the expected pattern of regional receptor modulation experienced greater clinical improvement than those who did not.

From animal models to human evidence

The AMPA receptor hypothesis of ketamine's action has circulated in neuroscience for years, but prior evidence came almost entirely from rodent studies. Demonstrating the same mechanism in living human brains closes a significant gap between preclinical research and clinical psychiatry. The results suggest that the animal models, at least in this case, were pointing in the right direction.

The habenula findings are particularly noteworthy. This tiny structure has attracted increasing attention as a hub for depression-related circuitry, and the observation that ketamine specifically reduces AMPA receptor density there aligns with theories about habenular overactivity driving depressive symptoms.

Toward a biomarker for treatment response

Not every patient with treatment-resistant depression benefits from ketamine. Predicting who will respond and who will not has been largely guesswork. The PET imaging approach used here could, in principle, serve as a biomarker for evaluating and predicting individual responses to ketamine treatment.

If a patient's baseline AMPA receptor pattern can predict their likelihood of responding to ketamine, clinicians could make more informed decisions about which patients to treat with this drug and which to direct toward other options. Given that ketamine carries risks including dissociative side effects and potential for abuse, better patient selection would have real clinical value.

Limitations and next steps

The study sample of 34 patients is modest, and the findings need replication in larger, more diverse populations. The PET tracer [11C]K-2 requires a cyclotron to produce and is not widely available, limiting near-term clinical adoption. And while the study establishes a correlation between receptor changes and symptom improvement, it does not prove causation. Other mechanisms may contribute to ketamine's antidepressant effects alongside AMPA receptor modulation.

Still, the ability to visualize and quantify receptor dynamics in living patients represents a meaningful advance in understanding how one of psychiatry's most important new tools actually works.